Related Experiment Video
Updated: May 11, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Natalizumab therapy for multiple sclerosis
Tobias Derfuss1, Jens Kuhle, Raija Lindberg
1Department of Neurology, University Hospital Basel, Basel, Switzerland. tobias.derfuss@usb.ch
Seminars in Neurology
|May 28, 2013
Summary
Natalizumab effectively treats relapsing remitting multiple sclerosis by blocking lymphocyte migration to the CNS. However, potential risks like progressive multifocal leukoencephalopathy (PML) require careful patient monitoring and risk stratification.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Natalizumab is a monoclonal antibody targeting lymphocyte migration into the central nervous system (CNS).
- It has demonstrated significant efficacy in treating relapsing remitting multiple sclerosis (RRMS).
Purpose of the Study:
- To review the efficacy and safety profile of natalizumab in RRMS treatment.
- To discuss adverse events, particularly progressive multifocal leukoencephalopathy (PML), and risk management strategies.
Main Methods:
- Review of clinical trial data and postmarketing surveillance of natalizumab in RRMS patients.
- Analysis of safety data, focusing on adverse events and PML risk stratification algorithms.
Main Results:
- Natalizumab shows excellent efficacy in RRMS, with some patients experiencing disease improvement.
- Potential adverse events include allergic reactions, infections, and a critical risk of PML.
- Risk stratification and management strategies for PML are crucial.
Conclusions:
- Natalizumab is a highly effective treatment for RRMS, but its use necessitates careful consideration of serious risks, especially PML.
- Risk assessment, patient monitoring, and management strategies are essential for safe natalizumab therapy.
- Guidance on initiating, continuing, or discontinuing natalizumab, and managing treatment cessation is provided.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...